Multiple Sclerosis
The Disease
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system that leads to paralysis and currently affects approximately 2.5 Million people world wide. The exact cause of MS is unknown and the disease is non-curable. The rising in disease prevalence and the technological advances are attracting the interest of pharmaceutical companies aiming at developing therapeutics targeting MS.
Evaluation Platforms
MOG induced Experimental Autoimmune Encephalomyelitis, EAE ,is an established animal model of multiple sclerosis reproducing the majority of the pathology features of human condition.
Induced EAE using TghIL17 mice expressing exclusively human IL17A or hTNFR1KI mice expressing exclusively human TNFR1 allows the evaluation of biologics targeting IL17A or TNFR1, both important determinants of the pathology development.
Read-Out Parameters
In vivo EAE scoring
Body weight measurements
Histopathological evaluation (qualitative)
Competitive Advantage
MOG induced EAE is an established animal model of multiple sclerosis reproducing the majority of the pathology features of human condition. Standardization and validation of the model by our experienced scientific personnel has provided reliable preclinical evaluation platforms for the efficacy assessment of candidate multiple sclerosis therapeutics. Induced EAE using humanized IL17 mice (TghIL17) or hTNFR1KI mice allows the evaluation of biologics targeting IL17 or TNFR1 respectively.
